# Kate Garrett > Kate Garrett is a seed investor at Stanford Byers Center for Biodesign backing Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Stanford Byers Center for Biodesign](https://shizune.co/investors/profile/stanford-byers-center-for-biodesign) - Location: Redwood City, United States - Total investments: 3 - Last investment: Apr 2026 - Lead investor: 100% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/kate-garrett-464920 Kate Garrett is a seed investor at Stanford Byers Center for Biodesign in Redwood City focused on Medical and Health Care. Prior to Biodesign Kate spent five years as a development engineer and project leader at Pathway Medical Technologies (Seattle, WA), a medical device company that designs and manufactures the JETSTREAM(tm) family of atherectomy devices. While at Pathway Medical Kate supported more than six 510(k) submissions and acted as the engineering lead on thedesign verification and validation phases of three projects including two commercially available products. Kate is named as an inventor on the patent for the second-generation technology utilized in all current products in the JETSTREAM(tm) family. While at Pathway Kate developed several bench-top test models, including a simulated thrombus model, used to substantiate the safety and efficacy of the JETSTREAM(tm) System. Kate has traveled to national and international clinical sites and assisted with a GLP animal study. One of Kate's last projects involved leading a 15-person multi-disciplinary project team to bring a new product from concept to commercial use and to develop a simulated bench model of a layered arterial wall. Prior to Pathway Medical, Kate completed her B.S. in Mechanical Engineering as part of the inaugural class at Franklin W. Olin College of Engineering (Needham, MA). As a senior capstone project at Olin College Kate worked with a team of engineers to develop a point-of-care diagnostic device for tuberculosis. Her team's success in creating a working prototype led to the award of a grant by the National Collegiate Inventors and Innovators Alliance. Kate is passionate about sports and spends her free time running and playing soccer, flag football and volleyball. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 1 | 33% | | Health Care | 1 | 33% | | Manufacturing | 1 | 33% | | Medical Device | 1 | 33% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 1 | 33% | | Series A | 1 | 33% | | Series B | 1 | 33% | ### Country | Country | Investments | Share | | --- | --- | --- | | France | 1 | 33% | | United States | 1 | 33% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | SquareMind | Come build the future of healthcare with us. | $18M | Seed | Apr 28, 2026 | | | Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | | Series B | Oct 07, 2025 | | | Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | $21M | Series A | Aug 15, 2024 | | 3 of 3 investments shown. ## Co-investors - [Adamed Pharma](https://shizune.co/investors/profile/adamed-pharma) — VC Fund, 1 deal together - [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together - [Calm/Storm VC](https://shizune.co/investors/profile/calm-storm-ventures) — VC Fund, 1 deal together - [LB Investment](https://shizune.co/investors/profile/lb-investment) — VC Fund, 1 deal together - [Senvest Management](https://shizune.co/investors/profile/rima-management) — VC Fund, 1 deal together - [Teampact ventures](https://shizune.co/investors/profile/teampact-ventures) — VC Fund, 1 deal together ## About Stanford Byers Center for Biodesign VC Fund 3 contacts available at Stanford Byers Center for Biodesign. | Name | Title | Profile | | --- | --- | --- | | Josh Makower | Co-Founder | https://shizune.co/investors/profile/josh-makower | | Kate Garrett | Assistant Director of Biodesign Innovation Fellowship | https://shizune.co/investors/profile/kate-garrett | | Richard Popp | Head, Section on Ethics & Policy | https://shizune.co/investors/profile/richard-popp | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ## FAQ ### What does Kate Garrett invest in? Kate Garrett invests primarily in Medical, Health Care and Manufacturing startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Kate Garrett last invest? The most recent investment recorded for Kate Garrett closed in Apr 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co